Abstract
AbstractSoy lecithin liposomes (SLP) were prepared and partially surface modified with methoxy polyethylene glycol‐cholesterol conjugate (mPEG‐Chol) to improve its poorly‐soluble‐water‐anticancer‐drugs delivery efficiency. Paclitaxel (PTX) was used as the model drug and the PTX/SLP@mPEG was successfully developed with the optimal mass ratio of mPEG‐Chol determined at 4% in the SLP@mPEG formulation. The optimal SLP@mPEG formulation had a particle size range of 161.80 ± 1.51 nm and a negative surface charge of −54.30 ± 1.40 mV. Besides, a sustained drug release profile of 72 h and an encapsulation efficiency of 87.48 ± 0.70% was recorded. Moreover, in vitro cytotoxicity assays demonstrated that SLP@mPEG is nontoxic and cytocompatible. Overall, these obtained results provide insights into the potential of SLP@mPEG as a platform for the development of more effective therapies against cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
